Cargando…

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment

Only recently low-grade serous carcinoma (LGSOC) of the ovary has been recognized as a disease entity distinct from the more common high-grade serous carcinoma (HGSOC), with significant differences in pathogenesis and clinical and pathologic features. The present study aimed at evaluating whether th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciucci, Alessandra, Zannoni, Gian Franco, Buttarelli, Marianna, Martinelli, Enrica, Mascilini, Floriana, Petrillo, Marco, Ferrandina, Gabriella, Scambia, Giovanni, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356537/ https://www.ncbi.nlm.nih.gov/pubmed/27462782 http://dx.doi.org/10.18632/oncotarget.10797

Ejemplares similares

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
por: De Donato, Marta, et al.
Publicado: (2020)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer
por: Petrillo, Marco, et al.
Publicado: (2015)

In search for biomarkers and potential drug targets for uterine serous endometrial cancer
por: Dinoi, Giorgia, et al.
Publicado: (2021)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
por: Buttarelli, Marianna, et al.
Publicado: (2022)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
por: Ciucci, Alessandra, et al.
Publicado: (2022)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer
por: Leonardi, Simona, et al.
Publicado: (2017)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019)

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2015)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
por: Ferrandina, G, et al.
Publicado: (2008)

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
por: Lucà, Rossella, et al.
Publicado: (2019)

Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role?
por: Ciucci, Alessandra, et al.
Publicado: (2014)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
por: Tocci, Piera, et al.
Publicado: (2019)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo?
por: Baranello, Cinzia, et al.
Publicado: (2012)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis
por: Ciccarone, Francesca, et al.
Publicado: (2022)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis
por: Autorino, Rosa, et al.
Publicado: (2018)

Prognostic Value of Mandard’s Tumor Regression Grade (TRG) in Post Chemo-Radiotherapy Cervical Cancer
por: Scaglione, Giulia, et al.
Publicado: (2023)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma
por: Shen, Yuanming, et al.
Publicado: (2022)

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
por: Ferrandina, G, et al.
Publicado: (2005)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sd9okpr98de0a0qemccfvbvgh9